Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TALON: Pembrolizumab and Low Dose Radiation in Prostate Cancer
NCT04569461Phase 2Withdrawn
- Sponsor
- Duke University
- Start
- Jun 2025
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in prostate cancer (PCa), sponsored by Duke University. Planned start Jun 2025; status: withdrawn.
02
Drugs
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04569461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04569461.